Literature DB >> 10854538

Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides.

A M Vázquez1, M R Gabri, A M Hernández, D F Alonso, I Beausoleil, D E Gomez, R Pérez.   

Abstract

We examined the antitumor effects of 1E10 monoclonal antibody, an anti-idiotypic IgG to an IgM monoclonal antibody, named P3, that reacts specifically with N-glycolyl-containing gangliosides and also recognizes antigens in human breast and melanoma tumors. Two murine tumor cell lines positive for the P3 antibody, F3II mammary carcinoma (BALB/c) and B16 melanoma (C57BL/6), were employed. In BALB/c mice, vaccination with several i.p. doses at 14-day intervals of 50 microgram of 1E10 coupled to keyhole limpet hemocyanin in Freund's adjuvant, significantly reduced s.c. tumor growth of F3II carcinoma cells and the number of spontaneous lung metastases. Also, the effect of 1E10 as a biological response modifier on tumor lung colonization was evaluated in C57BL/6 mice injected i.v. with B16 melanoma cells. Interestingly, i.v. administration of 10 microgram of uncoupled 1E10 antibody, 10-14 days after inoculation of B16 cells, dramatically reduced the number of experimental metastases in comparison with lungs from mice treated with an irrelevant IgG. The present data suggest that this 'non-internal image' anti-idiotypic monoclonal antibody may activate more than one mechanism of antitumor response against melanoma and mammary tumor cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854538     DOI: 10.3892/or.7.4.751

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

Review 1.  Tumour-associated carbohydrate antigens in breast cancer.

Authors:  Aurélie Cazet; Sylvain Julien; Marie Bobowski; Joy Burchell; Philippe Delannoy
Journal:  Breast Cancer Res       Date:  2010-06-08       Impact factor: 6.466

2.  Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer.

Authors:  Valeria I Segatori; Ana M Vazquez; Daniel E Gomez; Mariano R Gabri; Daniel F Alonso
Journal:  Front Oncol       Date:  2012-11-08       Impact factor: 6.244

Review 3.  NGcGM3 ganglioside: a privileged target for cancer vaccines.

Authors:  Luis E Fernandez; Mariano R Gabri; Marcelo D Guthmann; Roberto E Gomez; Silvia Gold; Leonardo Fainboim; Daniel E Gomez; Daniel F Alonso
Journal:  Clin Dev Immunol       Date:  2010-10-27

4.  Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer.

Authors:  Jorge L Soriano; Noyde Batista; Eduardo Santiesteban; Mayté Lima; Joaquín González; Robin García; Yohanka Zarza; María V López; Myriam Rodríguez; Jorge L Loys; Narciso Montejo; Frank Aguirre; Amparo Macías; Ana M Vázquez
Journal:  Int J Breast Cancer       Date:  2011-07-14

Review 5.  Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches.

Authors:  Jose L Daniotti; Aldo A Vilcaes; Vanina Torres Demichelis; Fernando M Ruggiero; Macarena Rodriguez-Walker
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

Review 6.  The Extracellular Matrix and Neuroblastoma Cell Communication-A Complex Interplay and Its Therapeutic Implications.

Authors:  Irena Horwacik
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

7.  Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.

Authors:  Ana M Vázquez; Ana M Hernández; Amparo Macías; Enrique Montero; Daniel E Gómez; Daniel F Alonso; Mariano R Gabri; Roberto E Gómez
Journal:  Front Oncol       Date:  2012-10-23       Impact factor: 6.244

8.  Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.

Authors:  Marcelo D Guthmann; Cecilia Venier; Darien Toledo; Valeria I Segatori; Daniel F Alonso; Leonardo Fainboim; Ana M Vázquez; Hector Ostrowski
Journal:  Front Immunol       Date:  2013-01-17       Impact factor: 7.561

Review 9.  Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents.

Authors:  Jose Luis Daniotti; Ricardo D Lardone; Aldo A Vilcaes
Journal:  Front Oncol       Date:  2016-01-07       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.